Amaryl: Effective Glycemic Control for Type 2 Diabetes
| Product dosage: 2mg | |||
|---|---|---|---|
| Package (num) | Per pill | Price | Buy |
| 30 | $1.23 | $36.98 (0%) | 🛒 Add to cart |
| 60 | $0.96 | $73.96 $57.62 (22%) | 🛒 Add to cart |
| 90 | $0.87 | $110.94 $78.26 (29%) | 🛒 Add to cart |
| 120 | $0.82 | $147.92 $98.90 (33%) | 🛒 Add to cart |
| 180 | $0.78 | $221.88 $141.04 (36%) | 🛒 Add to cart |
| 270 | $0.75 | $332.82 $202.10 (39%) | 🛒 Add to cart |
| 360 | $0.74
Best per pill | $443.76 $266.60 (40%) | 🛒 Add to cart |
| Product dosage: 3mg | |||
|---|---|---|---|
| Package (num) | Per pill | Price | Buy |
| 30 | $1.40 | $42.14 (0%) | 🛒 Add to cart |
| 60 | $1.12 | $84.28 $67.08 (20%) | 🛒 Add to cart |
| 90 | $1.01 | $126.42 $91.16 (28%) | 🛒 Add to cart |
| 120 | $0.96 | $168.56 $115.24 (32%) | 🛒 Add to cart |
| 180 | $0.91 | $252.84 $164.26 (35%) | 🛒 Add to cart |
| 270 | $0.89 | $379.26 $239.08 (37%) | 🛒 Add to cart |
| 360 | $0.87
Best per pill | $505.68 $312.18 (38%) | 🛒 Add to cart |
Amaryl (glimepiride) is a second-generation sulfonylurea oral antidiabetic medication indicated for the management of type 2 diabetes mellitus. It functions primarily by stimulating insulin release from the pancreatic beta cells and increasing peripheral tissue sensitivity to insulin. This medication is typically prescribed as an adjunct to diet and exercise when glycemic control cannot be achieved through lifestyle modifications alone. Its once-daily dosing regimen supports patient adherence and provides sustained 24-hour glycemic control, making it a cornerstone therapy in many treatment plans.
Features
- Active ingredient: Glimepiride
- Drug class: Sulfonylurea (second-generation)
- Administration: Oral tablet
- Available strengths: 1 mg, 2 mg, 4 mg
- Pharmacological action: Insulin secretagogue; increases peripheral glucose uptake
- Onset of action: Within 1 hour
- Duration of action: Up to 24 hours
- Bioavailability: Complete and linear
Benefits
- Provides effective and consistent 24-hour blood glucose lowering with a single daily dose.
- Demonstrates a lower incidence of severe hypoglycemia compared to some older sulfonylureas.
- May be used as monotherapy or in combination with other antidiabetic agents like metformin or insulin for synergistic effects.
- Helps reduce the risk of long-term microvascular complications (e.g., retinopathy, nephropathy, neuropathy) associated with chronic hyperglycemia.
- Supports patient adherence and quality of life through a simple, once-daily dosing schedule.
- Exhibits extrapancreatic effects that may contribute to improved insulin sensitivity in muscle and adipose tissue.
Common use
Amaryl is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. It is most effective in patients who have some residual pancreatic beta-cell function. It is commonly used as a first-line pharmacological agent after metformin or as initial drug therapy in patients for whom metformin is contraindicated or not tolerated. It is also frequently employed in dual or triple therapy regimens alongside other oral antihyperglycemic drugs or basal insulin when treatment goals are not met with monotherapy.
Dosage and direction
The initial recommended dose is 1–2 mg once daily, administered with the first main meal of the day (typically breakfast). The dosage should be titrated based on the patient’s glycemic response, with increments of 1 mg or 2 mg at 1–2 week intervals. The usual maintenance dose is 1–4 mg once daily. The maximum recommended dose is 8 mg once daily. Patients being transferred from other oral hypoglycemic agents should undergo a careful transition with appropriate monitoring. The direction is to swallow the tablet whole with a glass of water; it should not be split, crushed, or chewed unless advised by a physician for specific reasons.
Precautions
- The primary risk associated with Amaryl therapy is hypoglycemia. Risk is increased with skipped meals, irregular eating, strenuous exercise, alcohol consumption, renal impairment, hepatic insufficiency, adrenal or pituitary insufficiency, and in elderly or debilitated patients.
- Hemolytic anemia has been reported in patients with glucose-6-phosphate dehydrogenase (G6PD) deficiency; consider a non-sulfonylurea agent in these patients.
- Loss of glycemic control may occur during periods of stress such as fever, trauma, infection, or surgery; temporary insulin therapy may be required.
- Use with caution in patients with hepatic impairment, as glimepiride is extensively metabolized by the liver. Reduced clearance may increase the risk of hypoglycemia.
- Periodic monitoring of blood glucose and HbA1c is essential to assess therapeutic efficacy and safety.
- Inform patients about the potential for hypoglycemia and educate them on its recognition and management.
Contraindications
- Known hypersensitivity to glimepiride, other sulfonylureas, or any component of the formulation.
- Diabetic ketoacidosis, with or without coma. This condition requires insulin therapy.
- Type 1 diabetes mellitus.
- Severe renal impairment or end-stage renal disease.
- Severe hepatic impairment.
- Concomitant use with bosentan.
Possible side effect
The most common side effect is hypoglycemia. Other possible adverse reactions include:
- Gastrointestinal: Nausea, vomiting, a feeling of fullness, abdominal pain, diarrhea.
- Dermatological: Allergic skin reactions including pruritus, erythema, urticaria, and maculopapular eruptions. Photosensitivity reactions.
- Hematological: Rare cases of leukopenia, thrombocytopenia, hemolytic anemia, agranulocytosis, aplastic anemia, and pancytopenia.
- Hepatic: Elevated liver enzymes, hepatitis, jaundice (cholestatic and hepatocellular).
- Ophthalmic: Visual disturbances, especially at initiation of therapy, due to changes in blood glucose levels.
- Other: Dizziness, asthenia, headache.
Drug interaction
Amaryl has a significant potential for drug interactions that can either potentiate or weaken its hypoglycemic effect.
- Drugs that may increase hypoglycemic risk: Insulin, other oral antidiabetics, ACE inhibitors, anabolic steroids, chloramphenicol, coumarin derivatives, cyclophosphamide, disopyramide, fenfluramine, fibrates, fluoxetine, MAO inhibitors, pentoxifylline, phenylbutazone, azole antifungals, salicylates, sulfonamides, tetracyclines, tritoqualine, quinolone antibiotics.
- Drugs that may decrease hypoglycemic effect: Acetazolamide, barbiturates, corticosteroids, diazoxide, diuretics, epinephrine, estrogens, glucagon, isoniazid, niacin, oral contraindications, phenothiazines, phenytoin, rifampin, somatropin, sympathomimetics, thyroid hormones.
- Drugs that may either increase or decrease effect: Beta-blockers, clonidine, lithium salts, alcohol. Beta-blockers can also mask the tachycardic symptoms of hypoglycemia.
- Potentiation of anticoagulant effect: Glimepiride may potentiate the effect of coumarin derivatives.
Missed dose
If a dose is missed, it should be taken as soon as the patient remembers on the same day. However, if it is close to the time of the next scheduled dose, the missed dose should be skipped. The patient should never take a double dose to make up for a forgotten one, as this significantly increases the risk of severe hypoglycemia. Patients should be advised to maintain their regular meal schedule when a dose is taken late to avoid a mismatch between drug peak action and food intake.
Overdose
Overdose with Amaryl can lead to severe and prolonged hypoglycemia, which may present as sweating, tremor, blurred vision, hunger, anxiety, palpitations, slurred speech, confusion, seizures, coma, and can be life-threatening. Management is a medical emergency. Mild hypoglycemia without loss of consciousness or neurological findings should be treated with oral glucose and adjustment of drug dosage and/or meal patterns. Severe hypoglycemic reactions with coma, seizure, or other neurological impairment require immediate hospitalization and administration of intravenous glucose (50%) or intramuscular/subsutaneous glucagon. Continuous glucose infusion and close monitoring for at least 24–48 hours may be necessary due to the prolonged half-life of glimepiride.
Storage
Store Amaryl tablets at room temperature, between 15°C and 30°C (59°F and 86°F). Keep the medication in its original container, tightly closed, and protected from light, moisture, and excessive heat. Keep all medications out of the reach of children and pets. Do not flush medications down the toilet or pour them into a drain unless instructed to do so. Properly discard this product when it is expired or no longer needed.
Disclaimer
This information is for educational and informational purposes only and does not constitute medical advice. It is not a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition or medication. Never disregard professional medical advice or delay in seeking it because of something you have read here. The information provided is based on the drug’s prescribing information but may not be all-inclusive.
Reviews
(Note: As an expert medical document, this section presents a summary of clinical perspectives rather than individual patient testimonials.) Clinical trials and post-marketing surveillance have consistently shown Amaryl (glimepiride) to be an effective and generally well-tolerated agent for the management of type 2 diabetes. It is recognized for its once-daily dosing convenience and its ability to provide sustained glycemic control, leading to significant reductions in HbA1c levels. The risk of hypoglycemia, while present, is often cited as being comparatively lower than with older sulfonylureas like glyburide, particularly when initiated at a low dose and carefully titrated. Its utility in combination therapy regimens is a significant advantage, allowing for a tailored approach to diabetes management. Overall, it remains a valuable and frequently prescribed option within the therapeutic arsenal for type 2 diabetes.